Login
Register
Submit a Paper
Propose a Special lssue
Open Access
CASE REPORT
Remission of hormone-refractory prostate cancer attributed to Essiac
Division of Urology, The Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Address correspondence to Dr. Wigdan Al-Sukhni, c/o
Dr. Neil Fleshner, 610 University Avenue, Suite 3-130,
Toronto, Ontario, M5G 2M9 Canada
Canadian Journal of Urology 2005, 12(5), 2841-2842.
Download PDFAbstract
Essiac is a popular complementary and alternative medicine (CAM) that is utilized by many cancer patients in North America. Much anecdotal reporting exists about its cancer-fighting qualities, but so far no clinical trials have been preformed to validate those claims. We describe here the case of a 64-year-old man whose hormone-refractory prostate cancer responded well to Essiac tea.Keywords
Essiac, prostate cancer, remission
Cite This Article
APA Style
Al-Sukhni, W., Grunbaum, A., Fleshner, N. (2005). Remission of hormone-refractory prostate cancer attributed to Essiac. Canadian Journal of Urology, 12(5), 2841–2842.
Vancouver Style
Al-Sukhni W, Grunbaum A, Fleshner N. Remission of hormone-refractory prostate cancer attributed to Essiac. Can J Urology. 2005;12(5):2841–2842.
IEEE Style
W. Al-Sukhni, A. Grunbaum, and N. Fleshner, “Remission of hormone-refractory prostate cancer attributed to Essiac,” Can. J. Urology, vol. 12, no. 5, pp. 2841–2842, 2005.
Copyright © 2005 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
